Fitzsimons Innovation Community Member

Pharmaceutical Executive recently spoke with RheumaGen CEO Richard Freed about his career and the work the biotech is doing to find cures for autoimmune diseases.

Aurora City Council has approved a massive increase in allowable housing at Fitzsimons Innovation Community, a move intended to transform the bioscience campus into a full-fledged neighborhood. Fitzsimons CEO Kelly Brough called the change “an obligation” to honor the site’s history while shaping a future that attracts talent and builds community.

A change to the Fitzsimons Innovation Community’s master plan in Aurora will allow eight times more residential units to be built on the medical campus.The Aurora City Council on Monday approved an amendment to the general development plan that increases the Fitzsimons Innovation Community residential unit cap from 850 units to 7,266 new units. Changes…

A new approach for gene editing will get its shot in a common and chronic autoimmune disorder. Rheumatoid arthritis is an autoimmune disease that causes pain and swelling in the joints. It affects about one percent of the adult population. With its HLA gene editing approach, RheumaGen believes it can create a one-time cure for…

A startup is developing a new class of treatments for autoimmune diseases leveraging an approach to editing genes in the HLA family, which play a critical role in the immune system. RheumaGen, which spun out from the University of Colorado Anschutz Medical Campus, launched earlier this year with $15 million in Series A funding co-led…

Melissa Krebs, Ph.D., CEO and Founder of Community member GelSana, has been inducted into the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. ​This prestigious honor recognizes her pioneering advancements in cell-interactive biomaterials and their clinical translation, particularly in regenerative medicine and drug delivery technologies. Her innovative work is making significant strides…